Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A multicentric study looked into 179 poor responders who underwent antagonist protocol in ICSI cycles Gonadotrophines is started on day 2 with HMG until the day of HCG administration with starting dose 300IU to 450IU,with no pretreatment with OCPs or progestogens or estrogen.
GNRH antagonist (cetrorelix 0,25mg s.c, cetrotide, serono laboratories, Aubonne Switzerland) is given using flexible protocol, it is given when at least one follicle reaches size 14 mm to prevent premature lutenization ,until the day of hCG administration Ovarian ultrasound scans were performed using a 5.0-9.0 MHZ multi frequency trans vaginal probe to assess the ovarian response till the mature follicles reach18-20mm when hCG administration 10000 IU is given to induce final oocytes maturation , serum E2 is done on day of HCG trigger.
Trans vaginal ultrasound-guided oocyte retrieval is performed 34-36 hours after hCG injection.
Ultrasound -guided fresh embryo transfer is performed on day 3 or 5 after fertilization.
Progesterone support of luteal phase was commenced on the day of ovum pick up using prontogest 400 mg twice daily.
A multicentric study looked into 179 poor responders who underwent antagonist protocol in ICSI cycles
Induction of ovulation cycle:
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| AMH < 0.3 ng/ml | Active Comparator | Poor ovarian responders according to ESHRE consensus with serum AMH < 0,3 ng/ml |
|
| AMH 0.3 to 0.7 ng/ml | Active Comparator | Poor ovarian responders according to ESHRE consensus with serum AMH 0.3 to 0.7 ng/ml |
|
| AMH > 0.7 to 1 ng/ml | Active Comparator | Poor ovarian responders according to ESHRE consensus with serum AMH 0.7 to 1 ng/ml |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| GnRH antagonist | Drug | 0,25mg s.c, cetrotide, serono laboratories, Aubonne Switzerland) is given using flexible protocol, it is given when at least one follicle reaches size 14 mm to prevent premature lutenization ,until the day of hCG administration |
| Measure | Description | Time Frame |
|---|---|---|
| Number of the retrieved oocytes | number of oocytes retrieved 34 hours after HCG injection | 34 hours after HCG injection |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Any factor which may affect reproductive outcome other than that the patient is a poor responder will be excluded from the study, like:
10.Hepatic or renal dysfunction 11.Hypersenstivity to study medication ( GNRH antagonist) 12.Need to take medication that can influence ovarian stimulation 13.Endometriosis grade 3 or 4 14.Ovarian cyst> 10 cm.
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Ahmed Maged, MD | Contact | +2001005227404 | prof.ahmedmaged@gmail.com | |
| Radwa Fahmy, MD | Contact | radwafahmi@yahoo.com |
| Name | Affiliation | Role |
|---|---|---|
| Ahmed Maged, MD | professor | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Kasr Alainy medical school | Recruiting | Cairo | 12111 | Egypt |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Gonadotropins | Drug | started on day 2 of the menstrual cycle until the day of HCG administration(choriomon,IBSA10000IU)with starting dose 300IU to 450IU |
|
|
| Human chorionic gonadotropin | Drug | 10000 IU is given to induce final oocytes maturation when at least 2 follicles reached 14 mm or more |
|
|
| Embryo transfer | Procedure | 0ne to three grade 1 or 2 embryos were transferred on day 3 after oocyte retrieval. Embryo transfer was performed with a Wallace catheter (Smith Medical International Ltd, Hythe, Kent, UK) |
|
| Progesterone | Drug | vaginal prontogest 400 mg twice daily |
|
| ID | Term |
|---|---|
| C092464 | LHRH, Ac-Nal(1)-Cpa(2)-Trp(3)-Arg(6)-Ala(10)- |
| C062876 | cetrorelix |
| D006062 | Gonadotropins |
| D008596 | Menotropins |
| D006063 | Chorionic Gonadotropin |
| D004624 | Embryo Transfer |
| D011374 | Progesterone |
| ID | Term |
|---|---|
| D036361 | Peptide Hormones |
| D006728 | Hormones |
| D006730 | Hormones, Hormone Substitutes, and Hormone Antagonists |
| D006065 | Gonadotropins, Pituitary |
| D010908 | Pituitary Hormones, Anterior |
| D010907 | Pituitary Hormones |
| D010455 | Peptides |
| D000602 | Amino Acids, Peptides, and Proteins |
| D001688 | Biological Products |
| D045424 | Complex Mixtures |
| D010926 | Placental Hormones |
| D011257 | Pregnancy Proteins |
| D011506 | Proteins |
| D027724 | Reproductive Techniques, Assisted |
| D012099 | Reproductive Techniques |
| D013812 | Therapeutics |
| D008919 | Investigative Techniques |
| D011282 | Pregnenediones |
| D011283 | Pregnenes |
| D011278 | Pregnanes |
| D013256 | Steroids |
| D000072473 | Fused-Ring Compounds |
| D011083 | Polycyclic Compounds |
| D003339 | Corpus Luteum Hormones |
| D042341 | Gonadal Hormones |
| D045167 | Progesterone Congeners |
| D012739 | Gonadal Steroid Hormones |
Not provided
Not provided